Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Lassen Therapeutics has raised $85.0M in total funding. The most recent round was Series B. The last funding was announced in December 2023.
Lassen Therapeutics's investors include Catalio Capital Management, Longitude Capital, Frazier Healthcare Partners, Longwood Fund, Frazier Life Sciences.
Lassen Therapeutics is headquartered in San Diego, United States.
Lassen Therapeutics develops antibody biotherapeutics to help improve the lives of patients suffering from serious diseases.
Lassen Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lassen Therapeutics — Funding & Investors." VCBacked, December 19, 2023, https://www.vcbacked.co/company/lassen-therapeutics. Accessed October 29, 2026.
VCBacked. (2023). Lassen Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/lassen-therapeutics
{{cite web |title=Lassen Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lassen-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated